Scoop: Ex­e­Vir hits pause on lla­ma-de­rived Covid an­ti­body amid Omi­cron vari­ants, shifts fo­cus to sec­ond-gen work

Ex­e­Vir has re­turned to the draw­ing board af­ter paus­ing work on its first-gen­er­a­tion lla­ma-de­rived Covid-19 an­ti­body and is turn­ing its R&D fo­cus to­ward a pre­clin­i­cal …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER